Dr. Jain is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
6431 Fannin St
Suite Msb 1.134
Houston, TX 77030Phone+1 713-500-6500Fax+1 713-500-6497
Education & Training
- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2017
- Government Medical College VijayanagarClass of 2002
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2022 - 2027
- TN State Medical License 2022 - 2027
- WA State Medical License 2022 - 2027
- GA State Medical License 2022 - 2026
- LA State Medical License 2022 - 2026
- TX State Medical License 2017 - 2026
- American Board of Internal Medicine Internal Medicine
- Join now to see all
Clinical Trials
- A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients with Previously Untreated High-risk Mantle Cell Lymphoma Start of enrollment: 2022 Nov 18
Roles: Principal Investigator, Contact
- Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients Start of enrollment: 2023 Jan 25
Roles: Principal Investigator
- Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma Start of enrollment: 2020 Aug 07
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1 citationsAntibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.Rishika Prasad, Abdur Rehman, Lubna Rehman, Faezeh Darbaniyan, Viktoria Blumenberg
Blood. 2025-02-20 - High-risk MCL: recognition and treatment.Preetesh Jain, Michael Wang
Blood. 2025-02-13 - Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma.Charles Gaulin, Preetesh Jain, Ranjit Nair, Swaminathan P Iyer, Hun Ju Lee
Leukemia & Lymphoma. 2025-01-21
Abstracts/Posters
- Tumor Microenvironment Molecular Signatures That Define Therapeutic Resistance in Mantle Cell LymphomaPreetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLLPreetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell LymphomaPreetesh Jain, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age _ 65 years) with Mantle C...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma _ Cohort Study of 369 Patients61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Non-Bcl2 Mutations Are Predominant in Patients (pts) with Venetoclax Resistant Mantle Cell Lymphoma (MCL) _ Response and Clinical Outcomes in Ultra-Refractory MCL61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
- MD Anderson Research Highlights for December 6, 2021December 6th, 2021
- Chemo-Free Regimen Highly Active in Older Mantle Cell Lymphoma PatientsNovember 29th, 2021
- TKIs Linked to Increased Cardiovascular and Arteriothrombotic Events in Chronic-Phase CMLJuly 1st, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: